After selling Endotronix to Edwards, this CEO sees an ‘eye-popping’ cardiac opportunity

VahatiCor, led by CEO Harry Rowland (who previously sold Endotronix to Edwards Lifesciences), is developing the A-Flux reducer system to treat coronary microvascular dysfunction, a condition currently managed only with medication. The device targets patients without existing interventional options for chest pain relief.